trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['t-dxd', 'solid tumor']
#asco23
tissue-agnostic efficacy of t-dxd in advanced solid tumors with her2 amplification identified by cfdna testing 62 pts with 16 different cancer types orr 56.5% the excellent work of hiroya taniguchi and colleagues 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm